UNSPSC 51161713: Amiphenazole

This classification denotes a cns stimulant with the molecular formula C9H9N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7ZJ8PWY0XD, chemically known as 2,4-thiazolediamine, 5-phenyl- but generally known as amiphenazole, which bears US NIH Compound Identifier 10275. Amiphenazole most often comes in base and hydrochloride forms. European Medicines Agency schedules Amiphenazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05453MIG.

UNSPSC 51161713 Amiphenazole is a Commodity code that, based on recent state and local procurement activity, appears misaligned with actual market solicitations — no recent opportunities directly name amiphenazole as a procured item. The three substantive opportunities tagged to this code involve naloxone procurement, on-site pharmacy services delivery, direct-to-manufacturer prescription programs, and generic pharmaceutical supply contracts through cooperative purchasing arrangements. The actual work being bought under this code classification spans pharmaceutical supply and dispensing services rather than a single active pharmaceutical ingredient, suggesting either tagging inconsistency or downstream taxonomy drift in state and local procurement systems.

Soliciting bodies include county health departments (Seminole County, Florida), county government employee health plan administrators (Hall County, Georgia), state health agencies (Texas Health and Human Services Commission), and state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering contracts effective across multiple states including Oregon). Recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems with a July 26, 2023 response deadline; Hall County's RFQ/P #47-010 for on-site pharmacy services at the Hall County Government Family Health Center Clinic, with proposals due June 4, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 deadline. Activity is concentrated in the Southeast (Florida, Georgia) and Upper Midwest (Minnesota), with exploratory procurement also active in Texas. The code shows sparse, scattered recent activity with no clear concentration among repeat issuers or jurisdictions.